Home & Garden Pet Products Pet Health Care & Supplements

CTnI MYO CK-MB Test Kit

Price Negotiable
Price: To be negotiated
MOQ: To be negotiated
Delivery Time: To be negotiated
Brand: Combined detection reagent of troponin I, myoglobin and creatine kinase isoenzyme(cTnl/MYO/CK-MB)
Product Description

Combined Detection Reagent Of Troponin I,Myoglobin And Creatine Kinase Isoenzyme (Immunofluorescence Chromatography)

 

CTnI/MYO/CK-MB Overview


Troponin I/myoglobin/creatine kinase isoenzyme (cTnI/MYO/CK-MB) includes the detection of the following three indicators: troponin I (cTnI), myoglobin (MYO), creatine kinase Isoenzyme (CK-MB), the combined detection of these three items is of great significance in the early diagnosis of acute myocardial infarction (AMI) and other acute myocardial diseases.

 

National Academy of Clinical Biochemical Sciences (NACB) Practice Guidelines

All patients with suspected ACS should be tested for myocardial necrosis markers
Troponin is the first choice marker for the diagnosis of myocardial infarction
The combined application of myoglobin and specific myocardial necrosis markers (such as cTnI/CK-MB) helps to rule out or diagnose myocardial infarction more quickly

 

 

  MYO CK-MB cTnI
molecular weight 17.8KD 86KD 22.5KD
Rise time 1-2h 4-6h 3-6h
Peak time 6-9h 24h 12-16h
recovery time 18-30h 2-3d 4-10d
Clinical value 1.The most important indicator of early AMI exclusion
2. Diagnosis of AMI recurrence, the best index for evaluating the effect of reperfusion treatment
1.Estimate the size of the infarct or re-infarction
2. The most valuable markers of MI without ST-segment elevation
1.The first choice marker for AMI diagnosis
2. Judge the infarct size and carry out risk stratification

 

 

CTnI/MYO/CK-MB Clinical Significance


  • Contribute to the early diagnosis and risk stratification of acute coronary syndrome
  • Judging the area of myocardial ischemia injury
  • Differential diagnosis of various causes of chest pain
  • Monitoring of myocardial injury caused by various reasons
  • Evaluation of clinical efficacy of certain therapeutic drugs

 

Possibility of outcome  
cTnI CK-MB MYO Clinical possibility

+

+ + It can basically diagnose myocardial infarction/myocardial injury, and the occurrence time is within 12-24 hours;
+ + - It can basically be diagnosed as myocardial infarction/myocardial injury, the detection time is more than 1 day, and the detection window of MYO has passed
+ - - Myocardial infarction/myocardial injury has been onset for 2-3 days, and it is recommended to review after a few hours;
+ - + In patients with myocardial infarction/myocardial injury, the detection time may exceed 3 days for symptoms, and the patient has re-injury or enlarged infarct size;
- + + Early myocardial infarction/myocardial injury/muscle injury, it is recommended to review cTnI within 4-8 hours;

-

- + 1. Early myocardial infarction/myocardial injury, it is recommended to review cTnI within 4-8 hours;
2. It may be caused by other injury diseases, such as creation, skeletal muscle injury, liver and kidney disease;
- + - 1. For minor myocardial damage, it is recommended to review cTnI within 4-8 hours;
2. It may be a non-myocardial injury disease, and the detection time has passed the MYO window period;

-

- - Myocardial infarction/myocardial injury is basically ruled out. If it is highly suspected, it is recommended to review every 2-4 hours.

 

 

cTnI/MYO/CK-MB Performance Index


Detection range sample size Sample type Test time
cTnI MYO CK-MB 60μl Whole blood / serum / plasma 15min
0.1~50ng/mL 10~200ng/mL 0.8~100ng/mL

 

 

 

Application Department


Outpatient, emergency, physical examination center, cardiovascular, ICU, chest pain center and other departments

 

 

CTnI/MYO/CK-MB Clinical Comparison


 

 

Company profile


ZOS-F2100(Multi-Channel) 4ZOS-F2100(Multi-Channel) 5ZOS-F2100(Multi-Channel) 6ZOS-F2100(Multi-Channel) 7

Zhongxiu Science And Technology Co.,Ltd., is a high-tech enterprise engaged in the research and development, production and operation of in vitro diagnostic products. The in vitro diagnostic products developed by the company cover POCT series, microbial series, biochemical series and immune series reagents and supporting instruments.
The company has always adhered to the core concept of "fast and accurate, living up to life", committed to providing society with excellent products and services, and contributing to the cause of human health.

 

 

 

 

Get in Touch

Have questions about our products or want to discuss a custom order? Our team is ready to help you.

Company Henan Lantian Medical Supplies Co.,Ltd.
Location Office Address: Building 4, No. 51 Jingbei 3rd Road, Jingkai Zone, Zhengzhou City. Henan Province,China.
Contact Person chen

Request A Quote

Please check your email address.
Your message must be at least 20 characters.